Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Centriolar coiled-coil protein of 110 kDa (CP110) is a centrosomal protein encoded by the CCP110 gene in humans that localizes to the distal end of centrioles. It is a substrate for cyclin-dependent kinases and is essential for proper regulation of centriole duplication and the cell cycle. CP110 acts as a critical negative regulator of primary cilia assembly by capping the distal end of centrioles, thereby preventing unnecessary cilia formation in non-ciliated cells. Removal or loss of CP110 is necessary for cilia biogenesis and is involved in early steps such as subdistal appendage assembly and vesicle docking, though it may also play context-dependent roles as a positive regulator of ciliogenesis in vivo. Disruption of CP110 function can result in ciliopathies and is associated with disorders such as spinocerebellar ataxia 11. There are currently no known drugs that directly target this protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Centriolar coiled-coil protein of 110 kDa (CP110).